×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KMDA – kamada ltd. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KMDA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/12
11:07 am
kmda
Kamada (KMDA) had its "buy" rating reaffirmed by Benchmark Co..
Low
Report
Kamada (KMDA) had its "buy" rating reaffirmed by Benchmark Co..
3/11
02:15 pm
kmda
Kamada (KMDA) was given a new $11.00 price target by Stifel Nicolaus.
Low
Report
Kamada (KMDA) was given a new $11.00 price target by Stifel Nicolaus.
3/11
07:37 am
kmda
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy [Yahoo! Finance]
Low
Report
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy [Yahoo! Finance]
3/11
07:22 am
kmda
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth [Yahoo! Finance]
Low
Report
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth [Yahoo! Finance]
3/11
07:02 am
kmda
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
Medium
Report
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
3/11
07:00 am
kmda
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
Medium
Report
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
3/4
07:13 am
kmda
Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026 [Yahoo! Finance]
Low
Report
Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026 [Yahoo! Finance]
3/4
07:00 am
kmda
Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026
Low
Report
Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026
Date
Time
Symbol
Company Name
Action
%Chg
3/11/2026
07:00 am
kmda
kamada ltd. - ordinary shares
MISS
Report
-5.5%
kamada ltd. - ordinary shares
11/10/2025
07:00 am
kmda
kamada ltd. - ordinary shares
MISS
Report
2.8%
kamada ltd. - ordinary shares
8/13/2025
07:00 am
kmda
kamada ltd. - ordinary shares
BEAT
Report
-1.3%
kamada ltd. - ordinary shares
5/14/2025
07:00 am
kmda
kamada ltd. - ordinary shares
IN-LINE
Report
1.3%
kamada ltd. - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/13
05:04 pm
kmda
Form 3 KAMADA LTD For: Mar 13 Filed by: Livneh Nir
Neutral
Report
Form 3 KAMADA LTD For: Mar 13 Filed by: Livneh Nir
3/11
07:25 am
kmda
Form 20-F KAMADA LTD For: Dec 31
Low
Report
Form 20-F KAMADA LTD For: Dec 31
3/11
07:00 am
kmda
Form 6-K KAMADA LTD For: Mar 11
Medium
Report
Form 6-K KAMADA LTD For: Mar 11
12/18
07:00 am
kmda
Form 6-K KAMADA LTD For: Dec 18
Low
Report
Form 6-K KAMADA LTD For: Dec 18
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/21
Form 6-K KAMADA LTD For: Nov 21
13.5%
1/21 Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund 6.4%
12/9 Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product 4.5%
11/13 Q3/2019 9/30/2019 EPS 0.140 ZacksConsensus 0.090 ActVsEst 0.050 - Beat 3.9%
2/5 Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020 3.2%
11/12 Form 6-K KAMADA LTD For: Nov 12 2.7%
12/4 Form 6-K KAMADA LTD For: Dec 04 2.2%
10/25 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 2.0%
11/7 Kamada to Report Third Quarter 2019 Financial Results and Host Conference Call on November 13 1.3%
2/19 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 1.3%
1/21 Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund 6.4%
12/9 Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product 4.5%
11/13 Q3/2019 9/30/2019 EPS 0.140 ZacksConsensus 0.090 ActVsEst 0.050 - Beat 3.9%
2/5 Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020 3.2%
11/12 Form 6-K KAMADA LTD For: Nov 12 2.7%
12/4 Form 6-K KAMADA LTD For: Dec 04 2.2%
10/25 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 2.0%
11/7 Kamada to Report Third Quarter 2019 Financial Results and Host Conference Call on November 13 1.3%
2/19 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 1.3%
TOP News Decliners
3/11
Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology including its Commercial Anti-Rabies IgG and its Pipeline Products Anti-Corona (COVID-19) and Anti-Zika IgGs
-14.2%
2/12 Q4/2019 12/31/2019 EPS 0.130 ZacksConsensus 0.130 ActVsEst 0.000 - In-Line -8.2%
2/18 Form SC 13G/A KAMADA LTD Filed by: MEITAV DASH INVESTMENTS LTD -7.4%
1/7 Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance -5.4%
1/9 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.3%
12/2 Form SC 13D/A KAMADA LTD Filed by: Brosh Capital Partners L.P. -3.9%
12/16 Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency -3.8%
1/24 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.7%
10/29 Kamada and Kedrion Biopharma Announce Publication of Results from the Registration Study of KEDRAB® (Rabies Immune Globulin [Human]) in Human Vaccines & Immunotherapeutics Medical Journal -3.6%
12/23 Kamada Ltd. (NASDAQ: KMDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock. -3.0%
2/12 Q4/2019 12/31/2019 EPS 0.130 ZacksConsensus 0.130 ActVsEst 0.000 - In-Line -8.2%
2/18 Form SC 13G/A KAMADA LTD Filed by: MEITAV DASH INVESTMENTS LTD -7.4%
1/7 Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance -5.4%
1/9 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.3%
12/2 Form SC 13D/A KAMADA LTD Filed by: Brosh Capital Partners L.P. -3.9%
12/16 Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency -3.8%
1/24 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.7%
10/29 Kamada and Kedrion Biopharma Announce Publication of Results from the Registration Study of KEDRAB® (Rabies Immune Globulin [Human]) in Human Vaccines & Immunotherapeutics Medical Journal -3.6%
12/23 Kamada Ltd. (NASDAQ: KMDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock. -3.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: